[ Case Study ] · 2026
High-Throughput Antibody Expression Optimization
From VH/VL Assembly to Scalable Antibody Production in ExpiHEK293
A scalable workflow for rapidly screening, expressing, and selecting high-quality antibody candidates for downstream development.
Common Client Challenges
- Too many antibody candidates
- Limited screening capacity
- Poor expression yields
- Aggregation issues
- Delayed progression into functional studies
Integrated Workflow
- 01
VH/VL Assembly & Vector Construction
Golden Gate Assembly platform converts VH/VL sequences into sequence-confirmed HC/LC expression vectors. QC checkpoints include insert confirmation (colony PCR / restriction screening), plasmid quality (concentration, A260/280, endotoxin), full VH/VL Sanger sequencing, and construct verification (correct HC/LC pairing and reading frame).
- 02
High-Throughput Expression Screening
96 deep-well plate transfection in 2 mL ExpiHEK293 cultures with transfection controls, negative controls, and GFP controls. Optimization parameters include DNA amount, HC:LC ratio, reagent ratio, cell density, and expression duration, alongside expression monitoring of cell growth, viability, and antibody secretion level.
- 03
Mid-Scale Expression Confirmation
5 mL ExpiHEK293 scale-up to confirm expression reproducibility, Protein A concentration, and binding (ELISA, SPR, BLI). Protein quality is assessed for purity, fragmentation, and aggregation before scale-up.
- 04
Antibody Production Scale-Up
50–400 mL flask production with QC for Protein A purification yield, SEC-HPLC (monomer % and aggregation %), CE-SDS / SDS-PAGE for HC/LC integrity, and LC-MS for molecular weight confirmation.
- 05
Final Antibody Quality & Release
Purified antibody released for functional studies after a final QC panel covering purity & identity, developability assessment, and functional characterization.
Quality Control at Each Step
Expression titer
Purified yields of 100–450 µg/mL across a representative 10-mAb panel demonstrate consistent productivity in the ExpiHEK293 platform.
SDS-PAGE (reducing & non-reducing)
>95% purity with the expected HC/LC banding pattern under reducing conditions and intact IgG under non-reducing conditions.
Analytical SEC (aSEC)
>95% monomer purity with low high-molecular-weight species, confirming low aggregation across the panel.
Key Results
- Large antibody panels rapidly evaluated
- Early removal of poor expressers
- Integrated expression + quality ranking
- Selection based on high expression, high purity, low aggregation, and strong binding
- Fast transition from 2 mL screening to 5 mL confirmation to 50–400 mL production
Conclusion
Integrated Golden Gate Assembly, ExpiHEK293 expression, and staged QC enable better antibodies, faster — moving programs cleanly from 2 mL screening to 5 mL confirmation to 50–400 mL production with high-quality candidates ready for functional studies.
Frequently Asked Questions
What is high-throughput antibody expression screening?
High-throughput antibody expression screening is a workflow that produces and evaluates many antibody candidates in parallel — typically in 96 deep-well plates at 2 mL scale — so that productivity, binding, and quality data can be generated quickly across a large panel and used to triage candidates before committing scale-up resources.
Why use ExpiHEK293 for antibody production?
ExpiHEK293 is a transient mammalian expression system that delivers human-like post-translational modifications, scales cleanly from 2 mL screening wells to 50–400 mL flasks, and routinely produces 100–450 µg/mL titers — which makes it well suited for both early triage and downstream functional studies.
How do you select high-quality antibody candidates?
Candidates are ranked using an integrated score that combines expression titer, Protein A purification yield, monomer purity by SEC-HPLC / aSEC, HC/LC integrity by CE-SDS / SDS-PAGE, and confirmed target binding by ELISA, SPR, or BLI. Only candidates that pass all gates progress to scale-up and developability assessment.
What QC assays are used during antibody expression?
Staged QC includes insert and sequence verification at the vector stage; cell growth, viability, and secretion monitoring during expression; Protein A concentration, ELISA/SPR/BLI binding, and aggregation analysis at mid-scale; and SEC-HPLC, CE-SDS / SDS-PAGE, and LC-MS during scale-up, followed by a final purity, developability, and functional characterization panel.
Ready to accelerate your antibody panel?
Talk to our team about applying high-throughput ExpiHEK293 expression and integrated QC to your discovery program.